CytoDel

CytoDel is a preclinical-stage biopharmaceutical company based in New York, United States. It was founded to commercialize technology developed by its founders at the NYU-Grossman School of Medicine, and it holds an exclusive license from NYU to a patented and proprietary platform. That platform is based on producing recombinant botulinum toxin (rBoT) derivatives that are designed to address high-value medical needs. The company's core technology uses recombinant protein engineering to produce atoxic rBoT derivatives that retain the intraneuronal trafficking properties of native botulinum toxin but have a controllable safety profile customized to specific indications. CytoDel's lead program completely inactivates the protease responsible for the toxicity of native botulinum toxin, enabling the use of rBoTs to deliver therapeutic proteins to the cytoplasm of neurons. This approach is intended for conditions with high unmet medical need, including diseases of both the peripheral and central nervous system. CytoDel describes its rBoT platform as enabling a new class of antibody fusion proteins that specifically deliver their payload to previously inaccessible targets in the neuronal cytoplasm. The company's lead program applies intraneuronal delivery for biodefense, and it is additionally developing programs for the treatment of nervous system disorders and chronic pain. A second program is a Biobetter botulinum toxin offering an improved safety margin and outcomes for the treatment of large muscles and muscle groups. CytoDel has announced pre-clinical data on Cyto-111 as an antidote to botulinum neurotoxin (BoNT), published in Science Translational Medicine, and has completed a Series A financing. Its pipeline remains preclinical, and the company operates as a private biopharmaceutical developer.

CytoDel was founded to commercialize technology developed by its founders at the NYU-Grossman School of Medicine (NYU). The company holds an exclusive license from NYU to a patented and proprietary platform based on producing recombinant botulinum toxin (rBoT) derivatives that uniquely address high-value medical needs. Botulinum toxin (BoT) is best known as the active ingredient in pharmaceutical products such as Botox (AbbVie/Allergan). All current FDA-approved BoT pharmaceutical products are produced by fermentation of the native Clostridium botulinum bacteria, serotype A1. They therefore contain the same active ingredient and differ only in excipients, production and analytical methodology, and approved clinical indications. CytoDel instead utilizes recombinant protein engineering to produce atoxic rBoT derivatives that retain the intraneuronal trafficking properties of native BoT but have a controllable safety profile customized to specific indications. CytoDel's lead program completely inactivates the protease responsible for the toxicity of native (wild type) BoT, enabling the utilization of rBoTs to deliver therapeutic proteins to the cytoplasm of neurons for the treatment of conditions with high unmet medical need, including diseases of both the peripheral and central nervous system. The company's rBoT platform enables the creation of a new class of antibody fusion proteins that specifically deliver their payload to previously inaccessible targets in the neuronal cytoplasm. CytoDel's programs include a lead program utilizing intraneuronal delivery for biodefense, as well as programs for the treatment of nervous system disorders and chronic pain. A second program is a Biobetter BoT offering an improved safety margin and outcomes for the treatment of large muscles and muscle groups. The company has announced pre-clinical data on Cyto-111 as an antidote to botulinum neurotoxin (BoNT), published in Science Translational Medicine, and has completed a Series A financing. Its pipeline remains preclinical.

• CytoDel founded to commercialize technology developed at NYU-Grossman School of Medicine

• Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety published

• Engineering Botulinum Neurotoxin C1 as a Molecular Vehicle for Intra-Neuronal Drug Delivery published

• Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism published

• CytoDel Completes Series A Financing

• CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) Published in Science Translational Medicine

Preclinical biopharmaceutical company developing recombinant botulinum toxin derivatives for intraneuronal drug delivery, with applications in biodefense, nervous system disorders, and chronic pain.

• Cyto-111

  Preclinical antidote to botulinum neurotoxin (BoNT).

• rBoT platform

  Recombinant botulinum toxin derivatives for intraneuronal drug delivery.

• Biobetter BoT

  Improved safety margin and outcomes for treatment of large muscles and muscle groups.

1. 1CytoDel Inc.cytodel.com
2. 2About | Cytodelcytodel.com
3. 3CytoDel (United States)wikidata.org